Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink

Abstract

Our findings suggest that the two incretin-based therapies are not associated with an increased or decreased risk of depression or self-harm.